Advaxis, Inc. (Advaxis) is a development-stage company. The Company is a biotechnology company with the focus to develop immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under license from the University of Pennsylvania (Penn), which utilizes live attenuated Listeria monocytogenes (Listeria or Lm) , bioengineered to secrete antigen/adjuvant fusion proteins. These Lm -LLO strains use a fragment of the protein listeriolysin (LLO), fused to a tumor associated antigen (TAA) or other antigen of interest. It has focused its initial development efforts on therapeutic immunotherapies targeting human papillomavirus (HPV)-associated diseases: cervical intraepithelial neoplasia (CIN 2/3), recurrent or refractory cervical cancer, and head and neck cancer. In addition it has developed immunotherapies for prostate cancer, and HER2 expressing cancers, such as breast, gastric, bladder, brain, pancreatic and ovarian cancer.